Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients

The study aimed to evaluate the efficacy and safety of adalimumab in treating severe alopecia areata (AA) through a prospective, open-label, single-center pilot study involving three patients. Each patient received adalimumab subcutaneously for six months. The trial was halted after studies showed no improvement in AA with tumor necrosis factor α antagonists. One patient responded favorably, while the other two saw no benefit. Adalimumab was well tolerated but did not result in significant hair regrowth.